IRTC

IRTC

USD

iRhythm Technologies Inc. Common Stock

$181.100-1.580 (-0.865%)

Echtzeitkurs

Healthcare
Medizinprodukte
Vereinigte Staaten

Kursdiagramm

Loading Chart...

Schlüsselkennzahlen

Marktkennzahlen
Unternehmensfundamentaldaten
Handelsstatistiken

Marktkennzahlen

Eröffnung

$182.680

Hoch

$185.040

Tief

$177.740

Volumen

0.37M

Unternehmensfundamentaldaten

Marktkapitalisierung

5.8B

Branche

Medizinprodukte

Land

United States

Handelsstatistiken

Durchschnittliches Volumen

0.40M

Börse

NMS

Währung

USD

52-Wochen-Spanne

Tief $71Aktuell $181.100Hoch $212

Ähnliche Nachrichten

GlobeNewswire

iRhythm Technologies to Participate in Upcoming Investor Conferences

SAN FRANCISCO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today

Mehr anzeigen
iRhythm Technologies to Participate in Upcoming Investor Conferences
Analyst Upgrades

Canaccord Genuity Maintains Buy on iRhythm Technologies, Raises Price Target to $212

Canaccord Genuity analyst William Plovanic maintains iRhythm Technologies with a Buy and raises the price target from $193 to $212.

Mehr anzeigen
Canaccord Genuity Maintains Buy on iRhythm Technologies, Raises Price Target to $212
Analyst Upgrades

Citigroup Maintains Buy on iRhythm Technologies, Raises Price Target to $242

Citigroup analyst Joanne Wuensch maintains iRhythm Technologies with a Buy and raises the price target from $205 to $242.

Mehr anzeigen
Citigroup Maintains Buy on iRhythm Technologies, Raises Price Target to $242
Analyst Upgrades

JP Morgan Maintains Overweight on iRhythm Technologies, Raises Price Target to $240

JP Morgan analyst Allen Gong maintains iRhythm Technologies with a Overweight and raises the price target from $190 to $240.

Mehr anzeigen
JP Morgan Maintains Overweight on iRhythm Technologies, Raises Price Target to $240
Analyst Upgrades

iRhythm Well-Positioned For 2026 After Upbeat Results And Raised Outlook

iRhythm Technologies beat Q3 estimates with record revenue, raised its 2025 sales outlook, and gained analyst confidence with higher price targets.

Mehr anzeigen
iRhythm Well-Positioned For 2026 After Upbeat Results And Raised Outlook
Analyst Upgrades

Goldman Sachs Maintains Neutral on iRhythm Technologies, Raises Price Target to $202

Goldman Sachs analyst David Roman maintains iRhythm Technologies with a Neutral and raises the price target from $180 to $202.

Analyst Upgrades

Needham Maintains Buy on iRhythm Technologies, Raises Price Target to $244

Needham analyst David Saxon maintains iRhythm Technologies with a Buy and raises the price target from $193 to $244.